Today: 4 July 2026
Amphenol stock slips after Wall Street target hikes; earnings are the next test
16 January 2026
1 min read

Amphenol stock slips after Wall Street target hikes; earnings are the next test

New York, Jan 16, 2026, 14:09 ET — Regular session

Amphenol Corp (APH) shares dropped 1.1%, closing at $152.54 on Friday afternoon. The stock opened at $155 and moved within a range of $151.75 to $156.58, with roughly 5.4 million shares changing hands.

This shift is crucial since investors see Amphenol as a reliable source for data-center expansions, where high-speed connectors and cables are essential components. The key issue: will that demand stay strong this quarter, and can the newly acquired cable segment be smoothly integrated into the financials?

Amphenol on Thursday announced a mandatory “open offer” — a tender bid required under Indian takeover rules — to acquire up to 26% of ADC India Communications from public shareholders after gaining indirect control of the firm. The company set the offer price at 1,233.59 rupees per share (around $13.68), which could total about $16.4 million in cash if fully subscribed. The offer carries no minimum acceptance threshold. Business Wire

Goldman Sachs bumped up its price target on Amphenol to $183 from $165, maintaining a Buy rating. The upgrade is tied to what the firm calls “strong data center demand,” as noted in a research report shared by TheFly. TipRanks

BofA lifted its price target to $165 from $163 and kept a Buy rating, anticipating a quarterly beat alongside “conservative” guidance. The bank also bumped its fiscal 2026 revenue and EPS forecasts in the preview to $31.2 billion and $4.41, up from $30.0 billion and $4.21. TipRanks

UBS analyst Joseph Spak maintained a Buy rating and raised his price target to $174 from $152 in a note dated Jan. 14.

Earlier this month, the company wrapped up its acquisition of CommScope’s Connectivity and Cable Solutions business. CEO R. Adam Norwitt highlighted that the deal “adds significant fiber optic interconnect capabilities” for IT datacom and communications networks. Amphenol projects the unit will bring in around $4.1 billion in sales by 2026 and expects it to be roughly $0.15 accretive to earnings per share, excluding acquisition-related costs. Amphenol Investors

On Friday, TE Connectivity slipped 0.5%.

The SPDR S&P 500 ETF and Invesco QQQ ETF edged mostly flat, leaving the spotlight on individual company developments rather than broad market moves.

That said, the recent surge leaves the stock vulnerable if data-center orders slow or integration costs climb beyond what bulls anticipate. When expectations are razor-thin, even minor tweaks to guidance — management’s outlook — can weigh on the shares.

Amphenol’s scheduled fourth-quarter earnings call is set for Jan. 28 at 1:00 p.m. ET. Investors will be watching closely for any demand trends in IT and data communications, as well as initial insights into the cable unit’s performance.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Takeda Pharmaceutical (TSE:4502) Eyes Fair Value After 83.5% Five-Year Rise
    July 3, 2026, 6:09 PM EDT. Takeda Pharmaceutical shares are up 83.5% in five years, putting in strong gains for holders. But on valuation, the picture is mixed: Simply Wall St says it's undervalued on 4 of 6 counts. The stock trades at a P/S of 1.9x, a bit over the sector average but below its peers at 4.0x. Simply Wall St pegs a fair P/S at 3.4x, suggesting some room to move. Takeda's deal with Insilico Medicine for AI-driven drug discovery and a new CEO could matter for growth and outlook. Shares are up 25.6% in a year, giving some momentum, though risks around execution still weigh. Where the stock goes next may depend on whether the current price has baked in these factors or leaves space for more upside.
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed
Previous Story

Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Thermo Fisher Scientific stock slips into long weekend as TMO traders eye Jan. 29 earnings
Next Story

Thermo Fisher Scientific stock slips into long weekend as TMO traders eye Jan. 29 earnings

Go toTop